1-20 of 13705 Search Results for

How I treat

Follow your search
Access your saved searches in your account

Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles
Journal: Blood
Blood (2012) 119 (13): 3016–3023.
Published: 2012
... provides a class I, level of evidence B recommendation for dabigatran as an agent to prevent stroke in patients with atrial fibrillation. However, the guideline notes, “Because of the twice daily dosing and greater risk of nonhemorrhagic side effects … patients already taking warfarin with excellent INR...
Journal Articles
Journal Articles
Journal: Blood
Blood blood.2022017635.
Published: 2023
...: 202-776-0544 | Fax 202-776-0545 editorial@hematology.org How I Treat Multiple myeloma in the geriatric patient Tracking no: BLD-2022-017635-CR1 Thierry Facon (Centre Hospitalier Universitaire (CHU) Lille, Service des Maladies du Sang, University of Lille, France) Xavier Leleu (University of Poitiers...
Journal Articles
Journal: Blood
Blood (2023) 141 (2): 147–155.
Published: 2023
... . How I treat complement-mediated TMA . Clin J Am Soc Nephrol CJASN . 2022 ; 17 ( 3 ): 452 - 454 . 7. Elliott AM , du Souich C , Lehman A , . RAPIDOMICS: rapid genome-wide sequencing in a neonatal intensive care unit-successes and challenges . Eur J Pediatr . 2019 ; 178 ( 8...
Includes: Supplemental data
Journal Articles
Journal: Blood
Blood (2023) 141 (1): 39–48.
Published: 2023
.... 3 2 2022 3 12 2021 © 2023 by The American Society of Hematology 2023 Visual Abstract Edited by Associate Editor Robert Zeiser, this How I Treat series focuses on post–allogeneic transplant management of high-risk patients. These patients are at risk for relapse...
Journal Articles
Journal: Blood
Blood (2023) 141 (1): 1.
Published: 2023
...Robert Zeiser 6 9 2022 6 9 2022 © 2023 by The American Society of Hematology 2023 Edited by Associate Editor Robert Zeiser, this How I Treat series focuses on post–allogeneic transplant management of high-risk patients. These patients are at risk for relapse of malignancy...
Journal Articles
Journal: Blood
Blood (2023) 141 (1): 22–38.
Published: 2023
... © 2023 by The American Society of Hematology 2023 Visual Abstract Edited by Associate Editor Robert Zeiser, this How I Treat series focuses on post–allogeneic transplant management of high-risk patients. These patients are at risk for relapse of malignancy and severe graft-versus...
Journal Articles
Journal: Blood
Blood blood.2020008239.
Published: 2022
... * Corresponding Author; email: p.lugtenburg@erasmusmc.nl American Society of Hematology 2021 L Street NW, Suite 900, Washington, DC 20036 Phone: 202-776-0544 | Fax 202-776-0545 editorial@hematology.org How I treat Elderly Patients with DLBCL in the frontline setting. Tracking no: BLD-2020-008239-CR2...
Journal Articles
Journal: Blood
Blood blood.2022018521.
Published: 2022
... 2022 * Corresponding Author; email: jeffrey.carson@rutgers.edu American Society of Hematology 2021 L Street NW, Suite 900, Washington, DC 20036 Phone: 202-776-0544 | Fax 202-776-0545 editorial@hematology.org How I Treat Anemia with Red Blood Cell Transfusion and Iron Tracking no: BLD-2022...
Journal Articles
Journal: Blood
Blood blood.2021014818.
Published: 2022
... L Street NW, Suite 900, Washington, DC 20036 Phone: 202-776-0544 | Fax 202-776-0545 editorial@hematology.org How I Treat: Inpatient Consultations for Quantitative Neutrophil Abnormalities in Adults Tracking no: BLD-2021-014818-CR1 Rebecca Zon (Dana Farber Cancer Institute, United States) Nancy...
Journal Articles
Clinical Trials & Observations
Journal: Blood
Blood (2022) 140 (7): 673–684.
Published: 2022
... in the care of these patients, even as new therapeutic and preventative strategies become available. However, we acknowledge that this discussion has several limitations. First, understanding of COVID-19 is evolving, and the data provided in this “How I Treat” article are based on the available literature...
Journal Articles
Journal: Blood
Blood (2022) 140 (5): 438–444.
Published: 2022
... with iTTP in remission had at least mild symptoms of depression. 50 They also reported that 35% of patients with iTTP had a positive screening for posttraumatic stress disorder. It is presently unclear how to best screen for these complications in patients with iTTP to allow for interventions to mitigate...
Journal Articles
Journal: Blood
Blood (2022) 139 (21): 3138–3147.
Published: 2022
.... Druker BJ , Tamura S , Buchdunger E , . Effects of a selective inhibitor of the Abl tyrosine kinase on the growth of Bcr-Abl positive cells . Nat Med. 1996 ; 2 ( 5 ): 561 - 566 . 5. Cortes J , Kantarjian H . How I treat newly diagnosed chronic phase CML . Blood...
Journal Articles
Journal: Blood
Blood (2022) 139 (19): 2849.
Published: 2022
.... In this How I Treat series on plasma cell dyscrasias edited by Associate Editor Hervé Avet-Loiseau, experts in the field discuss the rapidly changing treatment landscape for multiple myeloma and light-chain amyloidosis. Using illustrative cases, they review the role of autologous transplant, novel combination...
Journal Articles
Journal: Blood
Blood (2022) 139 (19): 2918–2930.
Published: 2022
... of Hematology 2022 The treatment paradigms for multiple myeloma and amyloidosis have been transformed by novel therapies and continue to be modified in the face of new immunologic agents. In this How I Treat series on plasma cell dyscrasias edited by Associate Editor Hervé Avet-Loiseau, experts...
Journal Articles
Journal: Blood
Blood (2022) 139 (19): 2889–2903.
Published: 2022
... and amyloidosis have been transformed by novel therapies and continue to be modified in the face of new immunologic agents. In this How I Treat series on plasma cell dyscrasias edited by Associate Editor Hervé Avet-Loiseau, experts in the field discuss the rapidly changing treatment landscape for multiple myeloma...
Journal Articles
Clinical Trials & Observations
Journal: Blood
Blood (2022) 139 (19): 2882–2888.
Published: 2022
... The treatment paradigms for multiple myeloma and amyloidosis have been transformed by novel therapies and continue to be modified in the face of new immunologic agents. In this How I Treat series on plasma cell dyscrasias edited by Associate Editor Hervé Avet-Loiseau, experts in the field discuss the rapidly...
Journal Articles
Clinical Trials & Observations
Journal: Blood
Blood (2022) 139 (19): 2904–2917.
Published: 2022
... and continue to be modified in the face of new immunologic agents. In this How I Treat series on plasma cell dyscrasias edited by Associate Editor Hervé Avet-Loiseau, experts in the field discuss the rapidly changing treatment landscape for multiple myeloma and light-chain amyloidosis. Using illustrative cases...
Journal Articles
Journal: Blood
Blood (2022) 139 (15): 2294–2305.
Published: 2022
... , Campo E , Harris NL , , eds . WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues. Lyon, France : International Agency for Research on Cancer (IARC) ; 2017 : 226 - 228 . 2. Grever MR . How I treat hairy cell leukemia . Blood. 2010 ; 115 ( 1 ): 21 - 28...
Journal Articles
Journal: Blood
Blood (2022) 139 (10): 1427.
Published: 2022
...Laurie H. Sehn 19 1 2022 20 1 2022 21 1 2022 © 2022 by The American Society of Hematology 2022 Edited by Associate Editor Laurie Sehn, this How I Treat series features 5 state-of-the-art advisory pieces on how experts tackle recurring medical problems that may arise...